Aptar’s First Call Under New Leadership: The Naloxone Hole Is Closing, Beauty’s Is Not
Q3 core sales grew 5% and Q4 guidance implies a sharp rebound, but the easy comparison is doing more work than the strategy.
ATR · Earnings Call · 2026-10-30
A transitional quarter with a better setup
Aptar’s Q3 was not a blowout. Reported sales rose 6% to just over $1 billion, core sales rose 5%, and adjusted EPS fell 6% to $1.52 at comparable FX. Total revenue rose 6% year over year to just over $1 billion. The margin line is where the story lives: adjusted EBITDA margin fell to 21.3% from 23.2%, and operating margin was 12.3%, down 2.6 percentage points year over year. That is the price of losing high-margin emergency-medicine volume while Beauty and Closures still carry operational and mix drags.But the forward setup improved. Management said the emergency medicine destocking that has haunted Pharma for a year laps in Q4. Q4 EPS guidance of $1.39-$1.47 implies about 17% growth at the midpoint on a comparable-FX basis. That is a big number, and it is mostly a comparison, not a demand inflection.
Naloxone: the overhang finally gets a calendar date
This has been the central Aptar debate for four quarters. On the May call, management framed the $65 million full-year naloxone headwind as two-thirds first-half, one-third second-half: “By the time Q4 comes around, this should be almost washed out” — Stephan B. Tanda, President and CEO · 2026-05-01. On the prior February call, they said the post-destock baseline should grow at a “low to mid-single-digit growth rate from the new baseline” — Stephan Tanda, President and CEO · 2026-02-06. Q3 confirmed the timeline: Pharma core sales rose only 1%, but excluding emergency medicine they grew 8%; Injectables rose 9% and Consumer Healthcare rose 13%.The important nuance is that Naloxone is not coming back at its old growth rate. The new chief executive said the market is transitioning from prescription to OTC and generic, and the best guess is “GDP, GDP+ type growth” — Stephan Tanda, President & Chief Executive Officer · 2026-10-30. That is a permanent mix change, not a temporary inventory swing. Emergency medicine was described on the October 2025 call as “amongst the highest of the margins” — Vanessa Kanu, Executive Vice President and CFO · 2025-10-31 in Pharma. Losing that mix is why Pharma’s Q3 margin fell 80 basis points to 36.4% even as the rest of the portfolio grew.
Beauty is the real strategic test — and the new CEO knows it
The quarter’s most revealing moment was not the guidance. It was the answer on Beauty. Beauty core sales rose 8%, but adjusted EBITDA margin fell 70 basis points to 11.4%, and management again singled out North America. The new CEO was direct: “sales growth alone is not our objective. Our goal is to convert the strong demand for our products into more consistent profitability.” — Stephan Tanda, President & Chief Executive Officer · 2026-10-30 He also said the North American diagnostic is nearly complete, but the fix is not imminent.That is the right tone, but it is also a continuation. On the July call, when asked whether Aptar would take structural action in Beauty, the answer was: “it is too early. To commit to that.” — Stephan Tanda, President and CEO · 2026-07-31 The new CEO has now had two months and still will not put a plan or a timeline on the table. Investors should treat that as the central open item, not the Q4 EPS guide.that’s not going to be a fix, a quick fix. I mean, that’s not going to be a linear improvement. We have to do a transformation and that’s going to take time.
Closures had a cleaner story: core sales rose 11%, and the 15.5% margin was hit by 120 basis points of indexation pass-through; without it, margin would have improved 60 basis points. That is mechanical, not structural. Beauty is the opposite: subscale positions in growing categories, lost share with certain customers, and execution gaps. The company has fixed Europe and Asia; North America remains the hole.
The pipeline is real, but it is not a near-term margin lever
Management spent a large part of the call on Pharma’s pipeline: ophthalmic, nasal, inhalation, and injectables. There are concrete proof points — the Bausch & Lomb collaboration on Beat the Blink, the Massachusetts General Hospital nose-to-brain research, the Macquarie high-dose dry powder work, the Pulmatory acquisition, and the Stellanato system-level collaboration. The pipeline conversion story is credible, and the preserve formulation shift in ophthalmic is a genuine long-term opportunity. The new CEO also stressed that “around 90% of our business is repeat growing business” — Stephan Tanda, President & Chief Executive Officer · 2026-10-30, which is the economic engine behind the 7%-11% Pharma target.But pipeline language can obscure timing. The systemic nasal drug delivery category is still early; the acne treatment OTC switch is promising but not yet a material revenue line. The company is not predicated on one drug — “We are not predicated on any one drug” — Stephan Tanda, President & Chief Executive Officer · 2026-10-30 — but that also means no single catalyst will fix the near-term growth rate.
What the tape and balance sheet say
The shares are up 8.5% over the last 90 days into the print, but still about 22% below the November 2024 peak. At roughly 22x trailing net income, down 17% year over year, the market is not pricing a crisis — but it is also not giving management the benefit of the doubt on Beauty. The balance sheet is supportive but less cushioned than it looks: effective net cash was negative $919 million.The Russia deconsolidation was a one-off — a $61.2 million pre-tax charge, $0.94 per diluted share — and management excludes it from adjusted earnings. That is reasonable. The less reasonable interpretation would be to treat the Q4 guide as a clean acceleration. It is not. Q4 is seasonally softer, the tax rate is helped by previously unrecognized tax losses, and the emergency-medicine comparison is doing much of the work.